Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

BACKROUND: Patients with metastatic endometrial carcinoma have a poor prognosis and PIK3CA mutations and amplifications are common in these cancers. This study evaluated the efficacy and safety of the pure PI3K inhibitor BKM120 in advanced or recurrent endometrial carcinoma. METHODS: This phase II,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Heudel, P-E, Fabbro, M, Roemer-Becuwe, C, Kaminsky, M C, Arnaud, A, Joly, F, Roche-Forestier, S, Meunier, J, Foa, C, You, B, Priou, F, Tazi, Y, Floquet, A, Selle, F, Berton-Rigaud, D, Lesoin, A, Kalbacher, E, Lortholary, A, Favier, L, Treilleux, I, Ray-Coquard, I
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5294485/
https://ncbi.nlm.nih.gov/pubmed/28072765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.430
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars